The post Eli Lilly, Novo Nordisk and Merck: Buy, Sell or Hold? appeared first on 24/7 Wall St.. Among the pharma names investors debate most, Eli Lilly (NYSE:LLY) at $1,216.46 screens most constructively, Novo Nordisk (NYSE:NVO) at $45.92 looks range-bound, and Merck (NYSE:MRK) at $135.97 screens as fairly valued. All three trade in a market obsessed with GLP-1 economics and Merck’s KEYTRUDA patent cliff, and each has priced in a very different …